{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:20:06Z","timestamp":1792545606942,"version":"4.5.0"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.breast.2024.103725","type":"journal-article","created":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T18:55:22Z","timestamp":1712343322000},"page":"103725","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Phase II randomized trial comparing metronomic anthracycline-containing chemotherapy versus standard schedule in untreated HER2 negative advanced breast cancer: activity and quality of life results of the GOIM 21003 trial"],"prefix":"10.1016","volume":"75","author":[{"given":"Laura","family":"Orlando","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evaristo","family":"Maiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Orditura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Diana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliano","family":"Antoniol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Morritti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Aieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Ciccarese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Pisconti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Bordonaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Febbraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Schiavone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Quaranta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Caliolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Loparco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Cinefra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Colucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saverio","family":"Cinieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.breast.2024.103725_bib1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1158\/1055-9965.EPI-15-0578","article-title":"Global cancer incidence and mortality rates and trends: an update","volume":"25","author":"Torre","year":"2016","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"14","key":"10.1016\/j.breast.2024.103725_bib2","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1056\/NEJM199810013391407","article-title":"Treatment of breast cancer","volume":"339","author":"Hortobagyi","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2024.103725_bib3","article-title":"Single agent versus combination chemotherapy for metastatic breast cancer","author":"Carrick","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.breast.2024.103725_bib4","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1200\/JCO.2003.08.013","article-title":"Phase III trial of doxorubicin, paclitaxel and the combination of doxorubicin and paclitaxel as front line chemotherapy in metastatic breast cancer: an intergroup trial (E1193)","volume":"21","author":"Sledge","year":"2003","journal-title":"J Clin Oncol"},{"issue":"suppl. 5","key":"10.1016\/j.breast.2024.103725_bib5","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/annonc\/mdj974","article-title":"First line chemotherapy of metastatic breast cancer","volume":"17","author":"Pronzato","year":"2006","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.breast.2024.103725_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005006.pub3","article-title":"Different anthracyclines derivates for reducing cardiotoxicity in cancer patients","volume":"2010","author":"van Dalen","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.breast.2024.103725_bib7","doi-asserted-by":"crossref","unstructured":"Batist, B. G. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and multicenter trial of metastatic breast cancer. J Clin Oncol, 19(5), 1444\u20131454.","DOI":"10.1200\/JCO.2001.19.5.1444"},{"key":"10.1016\/j.breast.2024.103725_bib8","first-page":"1878","article-title":"Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer","volume":"60","author":"Browder","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.breast.2024.103725_bib9","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1172\/JCI9872","article-title":"Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumour angiogenesis in mice","volume":"105","author":"Hanahan","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1016\/j.breast.2024.103725_bib10","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/annonc\/mdf013","article-title":"Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels","volume":"13","author":"Colleoni","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2024.103725_bib11","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2147\/PROM.S156279","article-title":"The importance of patient-reported outcomes in clinical trials and strategies for future optimization","volume":"9","author":"Merciec","year":"2018","journal-title":"Patient Relat Outcome Meas"},{"key":"10.1016\/j.breast.2024.103725_bib12","doi-asserted-by":"crossref","unstructured":"Eton DT, Cella D, Yost KJ, Yount SE, Peterman AH, Neuberg DS et al. A combination of distribution- and anchor-based approaches determined minimally importantdifferences (MIDs) for dour endpoints in a breast cancer scales. J Clin Epidemiol 57 (9):898-910.","DOI":"10.1016\/j.jclinepi.2004.01.012"},{"issue":"12","key":"10.1016\/j.breast.2024.103725_bib13","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO guidelines committee","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.breast.2024.103725_bib14","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1001\/jamaoncol.2023.2150","article-title":"Efficacy of metronomic oral vinorelbine, cyclophosphamide, and capecitabine vs weekly intravenous paclitaxel in patients with estrogen receptor-positive, ErbB2-negative metastatic breast cancer","volume":"9","author":"Munzone","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.breast.2024.103725_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102569","article-title":"Novel endocrine therapies: what is next in estrogen receptor positive, HER2 negative breast cancer?","volume":"117","author":"Corti","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.breast.2024.103725_bib16","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s10549-021-06375-5","article-title":"Metronomic chemotharpy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study","volume":"190","author":"Cazzaniga","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"10.1016\/j.breast.2024.103725_bib17","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1007\/s11136-016-1284-8","article-title":"Assessing health-related quality of life in patients with breast cancer: a systematic and standardized comparison of available instruments using the EMPRO tool","volume":"25","author":"Maratia","year":"2016","journal-title":"Qual Life Res"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977624000560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977624000560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T18:46:31Z","timestamp":1715885191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977624000560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":17,"alternative-id":["S0960977624000560"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2024.103725","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II randomized trial comparing metronomic anthracycline-containing chemotherapy versus standard schedule in untreated HER2 negative advanced breast cancer: activity and quality of life results of the GOIM 21003 trial","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2024.103725","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103725"}}